StockData
Lexicon Pharmaceuticals, Inc. logo

Lexicon Pharmaceuticals, Inc. (LXRX) stock

LXRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 5/3087% above fair value
$1.78+0.03 (+1.71%)

Close on Nov 17, 2026Market cap $792.02MP/E –Yield –

Lexicon Pharmaceuticals cash

Cash and short-term investments held at the end of each period.

Lexicon Pharmaceuticals's cash was $190.61M at Jun 30, 2026. For fiscal 2025 it was $96.23M, down 59.6% from the year before. Over ten years it grew -15.5% a year on average. The highest annual figure on record is $521.35M in fiscal 2015.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$96.23M-59.6%
FY2024Dec 31, 2024$237.96M+40.0%
FY2023Dec 31, 2023$170.03M+22.9%
FY2022Dec 31, 2022$138.36M+59.5%
FY2021Dec 31, 2021$86.74M-43.0%
FY2020Dec 31, 2020$152.28M-43.9%
FY2019Dec 31, 2019$271.66M+69.7%
FY2018Dec 31, 2018$160.05M-48.5%
FY2017Dec 31, 2017$310.79M-10.3%
FY2016Dec 31, 2016$346.50M-33.5%
FY2015Dec 31, 2015$521.35M+53.6%
FY2014Dec 31, 2014$339.34M+162.8%
FY2013Dec 31, 2013$129.13M-42.1%
FY2012Dec 31, 2012$223.21M-20.8%
FY2011Dec 31, 2011$281.69M+33.4%
FY2010Dec 31, 2010$211.11M+109.9%
FY2009Dec 31, 2009$100.55M+17.1%
FY2008Dec 31, 2008$85.87M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$190.61M+13.5%
Q1 FY2026Mar 31, 2026$170.66M-12.4%
Q4 FY2025Dec 31, 2025$96.23M-59.6%
Q3 FY2025Sep 30, 2025$115.95M-55.1%
Q2 FY2025Jun 30, 2025$168.01M-45.8%
Q1 FY2025Mar 31, 2025$194.84M-45.2%
Q4 FY2024Dec 31, 2024$237.96M+40.0%
Q3 FY2024Sep 30, 2024$258.37M+18.3%
Q2 FY2024Jun 30, 2024$309.96M+20.7%
Q1 FY2024Mar 31, 2024$355.60M+235.7%
Q4 FY2023Dec 31, 2023$170.03M+22.9%
Q3 FY2023Sep 30, 2023$218.43M+60.4%
Q2 FY2023Jun 30, 2023$256.74M+314.3%
Q1 FY2023Mar 31, 2023$105.94M+22.5%
Q4 FY2022Dec 31, 2022$138.36M+59.5%
Q3 FY2022Sep 30, 2022$136.20M+12.6%
Q2 FY2022Jun 30, 2022$61.97M-47.7%
Q1 FY2022Mar 31, 2022$86.50M-38.8%
Q4 FY2021Dec 31, 2021$86.74M-43.0%
Q3 FY2021Sep 30, 2021$120.92M+8.5%
Q2 FY2021Jun 30, 2021$118.50M-41.3%
Q1 FY2021Mar 31, 2021$141.36M-43.3%
Q4 FY2020Dec 31, 2020$152.28M-43.9%
Q3 FY2020Sep 30, 2020$111.45M-62.4%
Q2 FY2020Jun 30, 2020$201.87M+90.5%
Q1 FY2020Mar 31, 2020$249.14M+87.1%
Q4 FY2019Dec 31, 2019$271.66M+69.7%
Q3 FY2019Sep 30, 2019$296.30M+58.2%
Q2 FY2019Jun 30, 2019$105.98M-56.5%
Q1 FY2019Mar 31, 2019$133.15M-49.2%
Q4 FY2018Dec 31, 2018$160.05M-48.5%
Q3 FY2018Sep 30, 2018$187.30M-4.8%
Q2 FY2018Jun 30, 2018$243.55M+5.3%
Q1 FY2018Mar 31, 2018$262.27M+1.0%
Q4 FY2017Dec 31, 2017$310.79M-10.3%
Q3 FY2017Sep 30, 2017$196.82M-50.2%
Q2 FY2017Jun 30, 2017$231.19M–
Q1 FY2017Mar 31, 2017$259.74M–
Q4 FY2016Dec 31, 2016$346.50M–
Q3 FY2016Sep 30, 2016$395.56M–

More Lexicon Pharmaceuticals figures

See a number that looks wrong?